Document Detail


Disease modification: promising targets and impediments to success.
MedLine Citation:
PMID:  23312415     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Osteoarthritis (OA) is a significant and growing concern to a large segment of the population. Effective treatments for slowing or stopping the progression of the disease are not available despite a great deal of investment-backed effort on the part of academia, government, and the pharmaceutical industry. Target selection has been problematic. Progress may also have been hindered to some extent by the prevalent cartilage-centric view of OA. Significant clinical development challenges remain for novel therapeutics in this area. This review elaborates on the challenges of disease-modifying OA drug development and points out specific therapeutic intervention strategies recently tried or currently being pursued.
Authors:
Gloria L Matthews
Related Documents :
24938865 - Multi-view singular value decomposition for disease subtyping and genetic associations.
24077055 - Contact investigation for active tuberculosis among child contacts in uganda.
24303905 - Heterogeneity in multiple transmission pathways: modelling the spread of cholera and ot...
23856995 - The primary glomerulonephritides: a systems biology approach.
3192585 - Synovial chondromatosis.
22154095 - Factors influencing self-management in chronic obstructive pulmonary disease: an integr...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Rheumatic diseases clinics of North America     Volume:  39     ISSN:  1558-3163     ISO Abbreviation:  Rheum. Dis. Clin. North Am.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8708093     Medline TA:  Rheum Dis Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  177-87     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Affiliation:
Orthopaedic & Regenerative Medicine Research, Genzyme, A Sanofi Company, 49 New York Avenue, Framingham, MA 01701, USA. Electronic address: gloria.matthews@sanofi.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Update on the role of muscle in the genesis and management of knee osteoarthritis.
Next Document:  Nonarthroplasty hip surgery for early osteoarthritis.